339 related articles for article (PubMed ID: 25099433)
1. Discounting of medicines in Australian community pharmacies.
Thai LP; Vitry AI; Moss JR
Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
[TBL] [Abstract][Full Text] [Related]
2. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
3. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
4. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
5. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?
Kanavos P; Taylor D
Curr Med Res Opin; 2007 Oct; 23(10):2467-76. PubMed ID: 17764613
[TBL] [Abstract][Full Text] [Related]
6. The price may not be right: the value of comparison shopping for prescription drugs.
Arora S; Sood N; Terp S; Joyce G
Am J Manag Care; 2017 Jul; 23(7):410-415. PubMed ID: 28817779
[TBL] [Abstract][Full Text] [Related]
7. Pharmacy practice in emergency response during the COVID-19 pandemic: Lessons from Australia.
Parajuli DR; Khanal S; Wechkunanukul KH; Ghimire S; Poudel A
Res Social Adm Pharm; 2022 Aug; 18(8):3453-3462. PubMed ID: 34810136
[TBL] [Abstract][Full Text] [Related]
8. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
9. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
Puig-Junoy J
Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
[TBL] [Abstract][Full Text] [Related]
10. Chronic conditions, financial burden and pharmaceutical pricing: insights from Australian consumers.
Whitty JA; Sav A; Kelly F; King MA; McMillan SS; Kendall E; Wheeler AJ
Aust Health Rev; 2014 Nov; 38(5):589-95. PubMed ID: 25099307
[TBL] [Abstract][Full Text] [Related]
11. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
12. Marketing cigarettes when all else is unavailable: evidence of discounting in price-sensitive neighbourhoods.
Burton S; Williams K; Fry R; Chapman K; Soulos G; Tang A; Walsberger S; Egger S
Tob Control; 2014 May; 23(e1):e24-9. PubMed ID: 24227539
[TBL] [Abstract][Full Text] [Related]
13. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
Robertson J; Walkom EJ; Henry DA
Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
[TBL] [Abstract][Full Text] [Related]
14. Variation of prescription drug prices in community pharmacies: A national cross-sectional study.
Larkin J; Moriarty F; McGuinness S; Finucane K; Fitzgerald K; Smith SM; O'Mahony JF
Res Social Adm Pharm; 2022 Oct; 18(10):3736-3743. PubMed ID: 35618647
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical counseling: Between evidence-based medicine and profits.
Egorova SN; Akhmetova T
Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727
[TBL] [Abstract][Full Text] [Related]
16. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Aust N Z J Public Health; 2009 Jun; 33(3):246-52. PubMed ID: 19630844
[TBL] [Abstract][Full Text] [Related]
17. Reasons why insured consumers co-pay for medicines at retail pharmacies in Pretoria, South Africa.
Mpanza NM; Bradley H; Laing R
Afr J Prim Health Care Fam Med; 2019 Mar; 11(1):e1-e6. PubMed ID: 31038333
[TBL] [Abstract][Full Text] [Related]
18. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
19. [What is the real price of SOP and OTC drugs? Pilot study on paracetamol].
Milozzi F; Di Filippo A; Cangini A; Trotta F
Epidemiol Prev; 2023; 47(1-2):57-66. PubMed ID: 36727257
[TBL] [Abstract][Full Text] [Related]
20. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan.
Lee YC; Huang KH; Huang YT
Health Policy Plan; 2007 Nov; 22(6):427-35. PubMed ID: 17901065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
